In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...
Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
The CEO of Novo Nordisk faced pointed questions about the cost of Ozempic and Wegovy on Capitol Hill Tuesday, as lawmakers ...
CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to ...
For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...
Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing ...
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...
Shares of Novo Nordisk (NVO) slipped on Friday following a note from JPMorgan's Richard Vosser. Vosser warned that the ...
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard ...